Replies to post #387236 on Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

This will still be a nice market to play in, but it will be a class 2 controlled substance like generic OxyContin. Per IQVIA, after generic entry and losing exclusivity, pricing is expected to drop 66% in 1st year and 74% during the 2nd year as competition ramps up (based on 12 years of oral drug info 2002-2014).

We’re not among the early birds, but hopefully early enough to start getting a piece of the pie. Within a very short timeframe, Vyvanse market may shrink smaller than Adderall ER market, where Elite hasn’t done a great job (unlike IR). Looking forward to seeing what Kirko can do with ER, but DEA has our back against wall.

https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/price-declines-after-branded-medicines-lose-exclusivity-in-the-us.pdf